Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351533 · ClinicalTrials.gov registry record · Phase 2
A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00351533: Completed Phase 2 study, sponsored by University of Washington.
NCT00351533 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00351533, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.
Primary Outcome
30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.
Interventions
- DRUG Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00351533 record still lists
NCT00351533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Fish oil (eicosapentaenoic acid and docosahexanoic acid) is the first listed.
NCT00351533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00351533 about?
NCT00351533 is a clinical study titled "A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)". The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.
What is the current status of trial NCT00351533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2006-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00351533?
The interventions under investigation include: Fish oil (eicosapentaenoic acid and docosahexanoic acid) (DRUG).
Who is sponsoring clinical trial NCT00351533?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00351533's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia